Trial Profile
A Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIP
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs P 9808 (Primary)
- Indications Acute intermittent porphyria
- Focus Biomarker; Pharmacodynamics
- Sponsors Zymenex A/S
- 12 Mar 2018 New trial record